The offer price represents a premium of 61.3% to Cordlife’s last-traded price of 15.5 cents on May 9. It also represents a premium of 61.3%, 60.3%, 59.2% and 61.3% to the volume weighted average price (VWAP) of the last one-, three-, six- and 12 month periods. The offer price is 42.9% above Cordlife’s 52-week high traded price of 17.5 cents as well.
Medeze Group, a leader in the Southeast Asian stem cell storage and services market, seeks to acquire a 10% stake in Mainboard-listed Cordlife Group amounting to 25.63 million shares. This marks the first initiative since Medeze’s listing on the Stock Exchange of Thailand in October 2024 to broaden the group’s regional footprint.
On May 13, the Thai-listed group, through its wholly-owned subsidiary Medeze Treasury Pte. Ltd., said it intends to make a voluntary conditional cash partial offer of 25 cents per share for the stake.
